Welcome to our dedicated page for Merit Med Sys SEC filings (Ticker: MMSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
Merit Medical Systems (MMSI) announced a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical. The total purchase consideration is $22 million, including $19 million cash at closing and up to $3 million in contingent payments tied to milestones.
The closing is expected in Q4 2025, subject to satisfaction or waiver of customary closing conditions. Merit referenced non-GAAP measures in its press release and stated that a quantitative reconciliation to GAAP is not available without unreasonable effort.
Merit Medical Systems has completed a planned leadership transition, appointing Martha G. Aronson as President and Chief Executive Officer effective October 3, 2025. The Board also expanded from ten to eleven members and named her to the Board, while longtime leader Fred P. Lampropoulos moves from President and CEO to Executive Chairman through January 3, 2026 and will remain Board Chair thereafter.
Aronson’s employment terms include a $1,000,000 annual base salary, a $250,000 signing bonus, eligibility for an annual bonus targeting 100% of salary (up to 200%), and participation in the long-term equity plan with an expected initial equity award valued at $5,500,000 plus an additional $4,125,000 in performance and restricted stock units. She will also receive a $12,000 monthly transition allowance through September 30, 2026 and relocation and legal fee reimbursements. Lampropoulos retains his existing compensation through the transition period, and a separate consulting agreement with additional compensation is under negotiation.
Martha Goldberg Aronson, President and CEO and a director of Merit Medical Systems, Inc. (MMSI), reported an amended Form 4 showing a grant of 19,594 restricted stock units (RSUs) on 10/03/2025. The RSUs carry no cash purchase price and vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to her continued service; each RSU converts to one share of common stock upon vesting. The Form 4/A was signed by an attorney-in-fact on 10/07/2025.
MERIT MEDICAL SYSTEMS INC filed an amended Form 3 for insider Martha Goldberg Aronson, who serves as President, CEO, and director. This amendment is an updated initial statement of her beneficial ownership in company securities and, based on the data provided, shows no reported transactions or share movements.
Martha Goldberg Aronson, President and CEO of Merit Medical Systems, Inc. (MMSI), received a grant of 19,594 restricted stock units (RSUs) on 10/03/2025. The RSUs were granted at a reported price of $0 and represent the contingent right to receive one share of common stock per RSU upon vesting. The award vests in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service. After the grant, the reporting person is shown as beneficially owning 19,594 shares directly. The Form 4 was submitted via attorney-in-fact on 10/07/2025.
Aronson Martha Goldberg filed an Initial Statement of Beneficial Ownership (Form 3) for Merit Medical Systems Inc. The filing lists her address in South Jordan, UT and identifies her role as President and CEO. The date of the event requiring the statement is 10/03/2025.
The filing discloses no securities beneficially owned by the reporting person at the time of this Form 3. The document was signed by an attorney-in-fact, Brian G. Lloyd, on 10/07/2025.
Merit Medical Systems insider transactions: The company's President and CEO, Fred P. Lampropoulos, reported multiple stock option exercises and share surrenders on 08/29/2025. He exercised 159,151 options at a $55.73 exercise price and an additional 2,000 options at $55.73, resulting in 159,151 and 2,000 underlying shares respectively that were reported as acquired. He also surrendered 124,824 shares (for payroll taxes and option payment) and his spouse surrendered 1,454 shares for the same purpose; neither surrender involved open-market sales. Post-transactions, Mr. Lampropoulos beneficially owned 1,204,779 shares directly and certain additional shares indirectly through spouse and 401(k) holdings. Several outstanding option grants with various exercise prices and vesting schedules remain.
Lynne N. Ward, a director of Merit Medical Systems, Inc. (MMSI), executed option exercises and share sales on 08/22/2025. She exercised 3,000 non-qualified stock options with a $34.46 exercise price, resulting in 3,000 shares acquired. The same day she sold 3,000 shares in multiple transactions at a weighted average price of $88.56. After these transactions she beneficially owned 12,809 shares. The exercised options were originally granted with a $34.46 strike and become exercisable in equal annual installments of 33% commencing 08/28/2020; the exercised tranche had an expiration date of 08/28/2026.
Merit Medical Systems, Inc. (MMSI) Form 144 notice reports a proposed sale of 3,000 common shares valued at $265,683 to be sold through Morgan Stanley Smith Barney on NASDAQ on 08/22/2025. The filing states these shares were acquired the same day via stock option exercise and paid for in cash. The filer represents no undisclosed material adverse information about the issuer. The filing also lists a prior sale by Lynne Ward of 2,433 shares on 08/11/2025 for $206,535.91. Outstanding shares are listed as 59,219,117.
Lynne N. Ward, a director of Merit Medical Systems (MMSI), reported transactions dated 08/11/2025 on a Form 4. The filing shows the exercise of non-qualified stock options with an exercise price of $34.46 and an associated acquisition of 2,433 shares, and a contemporaneous sale of 2,433 shares at $84.8894.
Following the reported activity the form lists non-derivative beneficial ownership figures of 15,242 and 12,809 shares (as reported on separate lines) and indicates 3,000 derivative securities beneficially owned after the transactions, with 5,433 underlying common shares referenced for the options. The form is signed by an attorney-in-fact on 08/12/2025.